Clinical Value of Detecting ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia Based on High-Throughput Sequencing Technology
10.19746/j.cnki.issn1009-2137.2024.01.042
- VernacularTitle:基于高通量测序技术检测慢性髓性白血病患者ABL激酶区突变的临床价值
- Author:
Ling ZHOU
1
;
Jun-Liang WANG
;
Xian-Wei WANG
;
Yang-Wei LI
;
Zhe ZOU
;
Yan-Li ZHANG
;
Xiao-Dong LYU
Author Information
1. 郑州大学附属肿瘤医院,河南省肿瘤医院中心实验室,河南郑州 450008
- Keywords:
chronic myeloid leukemia;
tyrosine kinase inhibitors;
ABL kinase domain mutations;
high-throughput sequencing;
Sanger sequencing
- From:
Journal of Experimental Hematology
2024;32(1):262-268
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the efficacy and clinical value of high-throughput sequencing(HTS)and Sanger sequencing in detecting ABL kinase domain mutations in patients with chronic myeloid leukemia(CML).Methods:A total of 198 samples of 147 CML patients from July 2017 to March 2021 in Henan Cancer Hospital were collected and underwent high-throughput sequencing and Sanger sequencing to detect the mutations in ABL kinase domain,and the relevant clinical data were collected for comparative analysis.Results:The proportion of total mutations and ≥ 2 mutations detected by high-throughput sequencing were significantly higher than those detected by Sanger sequencing(P=0.01;P=0.046).≥ 2 mutations were detected in 22 cases,of which 5 cases(22.7％)had compound mutations.High-throughput sequencing can detect low level mutations that cannot be detected by Sanger sequencing.In 198 samples,25(12.6％)were low level mutations,33(16.7％)were high level mutations and 10(5.1％)were mixed high and low level mutations.In the analysis of related clinical factors,the total mutation rate and the low level mutation rate in the optimal period,failure period and warning period were gradually increased(total mutation rate,P=0.016;low level mutation rate,P=0.005).The mutation rate of the samples with additional chromosomal abnormalities was also significantly increased(P=0.009).The mutation rate of patients who received first-and second-line treatment was significantly lower than that of patients who received third-or higher-line treatment(P=0.006).Analysis based on variant allele frequency(VAF)of the mutation site was helpful to visually evaluate the clonal evolution status of TKI-resistance CML cells.Conclusion:High-throughput sequencing is more sensitive and accurate than Sanger sequencing in mutation detection,which is helpful to accurately and visually evaluate TKI treatment response and optimize treatment strategy for CML.
